Output only Markdown formatted for MDX. Do not include any JSON, commentary, or explanations.

Gem Aromatics Q1FY27: Revenue up, margins down as Dahej scale-up begins

Gem Aromatics entered FY27 with year-on-year revenue growth, but the quarter also showed the cost of a major expansion before the full benefits arrive. In Q1FY27, standalone revenue from operations rose to Rs 83.0 crore, up 9 percent year on year, while consolidated revenue increased to Rs 98.9 crore, up 13 percent. The difference was profitability. Standalone PAT was Rs 7.3 crore, up 11 percent, but the consolidated business reported a loss of Rs 7.9 crore.

Management framed Q1 as a seasonally softer quarter and highlighted two pressures. One was product mix and higher raw material costs, particularly in the clove business after supply disruptions in Madagascar. The other was the early-stage cost base of the newly commissioned manufacturing platform at Dahej under its wholly owned subsidiary Krystal Ingredients Pvt. Ltd. The company noted that consolidated profitability was impacted by higher non-cash depreciation of Rs 9.1 crore following capitalisation of about Rs 265 crore of the Dahej capex, out of a planned roughly Rs 270 crore.

What the quarter said about demand and the operating environment

Demand trends were described as normalising, with management noting that Q1 has historically been softer because the larger mint vertical starts around May and June. On the export side, management said demand from the Western Hemisphere, largely the US and Latin America, was ramping up.

The clove vertical faced a temporary supply shock. Floods and cyclone-like conditions in Madagascar delayed incoming raw material shipments and pushed up prices, which also affected sales. Management said the situation normalised from May onward as ports reopened and material started flowing again, though shipping challenges remained a broader issue.

Margins reflected these pressures. Standalone gross margin fell to 17.7 percent from 25.0 percent a year ago, and standalone EBITDA margin declined to 10.3 percent from 13.8 percent. Consolidated gross margin declined to 16.7 percent from 29.5 percent, and consolidated EBITDA margin fell to 3.3 percent from 17.0 percent.

Financial snapshot: standalone stability versus consolidated drag

The headline difference between standalone and consolidated results came from Krystal Ingredients’ ramp-up phase. The company stated that the new facility carried a higher operating cost base while newer product verticals were still progressing through commercialisation and customer qualification.

The company also reported cash PAT of Rs 8.9 crore on a standalone basis and Rs 1.3 crore on a consolidated basis.

Dahej and Krystal Ingredients: the near-term pain and the intended pivot

The strategy section of the investor presentation is clear about what Gem Aromatics is trying to become. It positions itself as a specialty ingredients manufacturer with a wide portfolio across mint, clove, phenol, and other natural and synthetic ingredients. The growth narrative now centres on moving up the value chain into higher value specialty molecules, reducing dependence on the traditional mint portfolio, and using the multipurpose capabilities at Dahej to respond to evolving customer needs.

The company described Dahej as a next-generation platform using vapor phase technology and emphasised advantages such as proximity to phenol supply, port connectivity, and the ability to deploy the plant for varied models such as CRO, CMO and CDMO. It also stated that the Dahej unit benefits from a 15 percent corporate tax rate under government incentives.

But in the near term, the company is in the middle of a commercialisation cycle. Management repeatedly highlighted that customer audits, approvals, qualification and stability testing are central milestones before recurring volumes become visible.

New product verticals and timelines disclosed

Gem Aromatics provided specific quarter-linked expectations for three new verticals at Krystal.

First, cooling agents. Customer audits are completed and initial orders have been secured for GEM Cool 03, GEM Cool 05 and GEM Cool 23. The company expects revenue contribution from Q3FY27.

Second, citral chemistry led by Safranal. The company stated that Safranal revenue contribution is expected toward the end of Q2FY27 and more meaningfully from Q3FY27.

Third, phenol derivatives. Trial production is expected by the end of Q2FY27, followed by approvals and quality processes. Commercial production is targeted in Q3FY27, with revenue contribution expected from Q4FY27.

Management also addressed how investors should think about the ramp. On the call, it described FY27 as a ramp-up year and stated it did not want to guide on FY27 revenue or margins yet. However, it did make one directional statement: Krystal products are expected to be more than 50 percent of overall revenue in FY28.

Base business mix and global footprint

The presentation disclosed FY26 revenue distribution across major product groups. Mint and mint derivatives remained the largest segment at Rs 237 crore, representing about 65 percent of total revenue. Clove and clove derivatives contributed Rs 85 crore, about 23 percent. Natural and synthetic ingredients contributed Rs 36 crore, about 10 percent, and phenol derivatives contributed Rs 5 crore, about 1 percent.

This mix shows why management is pushing into higher value segments. The phenol derivatives line is small today but is presented as a high-value chemistry opportunity.

On geography, the company reported an FY26 revenue split of India 56 percent, the US 28 percent, Brazil 6 percent, China 7 percent, and rest of world 3 percent. It also reported serving 240 domestic customers and 44 international customers across 20 countries.

A key corporate development in this context was the approval to incorporate a wholly owned subsidiary in Brazil to distribute essential oils, aromatic chemicals and specialty chemicals. Management said the platform is expected to strengthen its distribution reach across Brazil and Latin America.

What to track from here

Gem Aromatics’ Q1FY27 commentary suggests that the next few quarters are less about headline growth and more about validating the Dahej investment through customer approvals and repeat order flow. Management linked margin recovery to a combination of improving utilisation and product mix shifting toward higher value products.

There are also clear near-term risks disclosed by the company. Clove raw material sourcing can face disruption, as seen in the Madagascar event. Shipping delays can impact the timing of export revenue recognition. And the qualification cycles for multinational customers can be long, especially for products that require stability testing and step-up ordering.

At the same time, the company’s disclosures offer a measurable framework for tracking execution. Cooling agents are expected to start contributing in Q3FY27. Safranal is expected to contribute from late Q2FY27 and more meaningfully from Q3FY27. Phenol derivatives are expected to start commercial production in Q3FY27 with revenue contribution expected in Q4FY27.

The Q1 numbers reflect the current cost load of the expanded platform. The investment case, as positioned by management, rests on whether the Dahej platform can convert customer engagement into recurring commercial supplies, and whether that shift can pull consolidated margins back up as the year progresses and into FY28.